Evidence map›Paper›PMID 31419696›Full record

ArticleTranslational oncology2019

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.

Elisa Napolitano Ferreira, Rafael Canfield Brianese, Renan Valieris Bueno de Almeida, Rodrigo Duarte Drummond, Jorge Estefano de Souza, Israel Tojal da Silva, Sandro José de Souza, Dirce Maria Carraro

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Impact ofCancers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Elisa Napolitano FerreiraCIPE, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Rafael Canfield BrianeseCIPE, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Renan Valieris Bueno de AlmeidaCIPE, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Rodrigo Duarte DrummondCIPE, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Jorge Estefano de SouzaInstituto Metrópole Digital, Federal University of Rio Grande do Norte, Natal, RN, Brazil; Bioinformatics Multidisciplinary Environment (BioME), Federal University of Rio Grande do Norte, Natal, RN, Brazil.
Israel Tojal da SilvaCIPE, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Sandro José de SouzaBioinformatics Multidisciplinary Environment (BioME), Federal University of Rio Grande do Norte, Natal, RN, Brazil; Brain Institute, Federal University of Rio Grande do Norte, Natal, RN, Brazil.
Dirce Maria CarraroCIPE, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil; National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, SP, Brazil. Electronic address: dirce.carraro@accamargo.org.br.
AC Camargo Hospital · BRUniversidade Federal do Rio Grande do Norte · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of the hereditary triple-negative breast cancers (TNBCs) are associated with BRCA1 germline mutations. Nevertheless, the understanding of the role of BRCA1 deficiency in the TNBC tumorigenesis is poor. In this sense, we performed whole-exome sequencing of triplet samples (leucocyte, tumor, and normal-adjacent breast tissue) for 10 cases of early-onset TNBC, including 5 hereditary (with BRCA1 germline pathogenic mutation) and 5 sporadic (with no BRCA1 or BRCA2 germline pathogenic mutations), for assessing the somatic mutation repertoire. Protein-affecting somatic mutations were identified for both mammary tissues, and Ingenuity Pathway Analysis was used to investigate gene interactions. BRCA1 and RAD51C somatic promoter methylation in tumor samples was also investigated by bisulfite sequencing. Sporadic tumors had higher proportion of driver mutations (≥25% allele frequency) than BRCA1 hereditary tumors, whereas no difference was detected in the normal breast samples. Distinct gene networks were obtained from the driver genes in each group. The Cancer Genome Atlas data analysis of TNBC classified as hereditary and sporadic reinforced our findings. The data presented here indicate that in the absence of BRCA1 germline mutations, a higher number of driver mutations are required for tumor development and that different defective processes are operating in the tumorigenesis of hereditary and sporadic TNBC in young women.

Identifiers

PMID31419696
PMCPMC6706625
OpenAlexW2967531351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.